UKI NETS

UK and Ireland Neuroendocrine Tumour Society

Become a member?

Join Now

Members’ Area

Log In

Search

About UKI NETS
Membership
News & Events
Clinical Practice
- ENETS Guidelines
Research
NETs for Newcomers
- Faculty Members
- Educational Event Endorsement
Nurses and Allied Health Professionals
- ENETS Nurse Group
Patient Advocacy
Contact

About UKI NETS
Membership
News & Events
Clinical Practice
- ENETS Guidelines
Research
NETs for Newcomers
- Faculty Members
- Educational Event Endorsement
Nurses and Allied Health Professionals
- ENETS Nurse Group
Patient Advocacy
Contact

12 January 2021

Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor.

« Perspectives of patients and physicians about neuroendocrine tumors. A qualitative study
Assessment of Therapy-Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy- A Systematic Review. »

Recent News

Neuroendocrine Cancer UK launches NCUK Academy Nurse Course
CALLING ALL MEMBERS – CAST YOUR VOTE!
UK Oncology Forum – 21st -22nd October
Registration open now for KHP NET Centre 8th Annual Meeting
UKI NETS 19th Annual Conference 2021 – Terms and Conditions of Virtual Event Participation

Sign up for our newsletter

Sign-up for our email newsletter. Simply give us your email address in the box below to sign-up.

Email

Links

Disclaimer & Copyright
Privacy Policy

Friends of UKI NETS

NET Cancer Day
Neuroendocrine Cancer UK
ENETS
AMEND
Cancer 52

Details

© 2016 UKI NETS
Do not reproduce without permission
Thanks to our design agency Dusted

Address

UK & Ireland Neuroendocrine Tumour Society Company limited by guarantee. Registered in England & Wales. Company number 6672185 Registered office address: Athenia House, 10-14 Andover Road, Winchester, Hampshire, England, SO23 7BS. The UK and Ireland Neuroendocrine Tumour Society was registered with the Charity Commission on 16 July 2012, charity registration number 1148145.